Background: Cutaneous adverse reactions are frequently induced by mogamulizumab. Cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and severe photosensitivity related to mogamulizumab have been reported. This study investigated whether severe radiation-induced dermatitis occurred in patients undergoing radiotherapy after the administration of mogamulizumab for adult T-cell leukaemia/lymphoma. Methods: We retrospectively reviewed 46 courses of radiotherapy administered to 15 consecutive patients with adult T-cell leukaemia/lymphoma (acute, n = 7; lymphoma, n = 7; smouldering, n = 1) who received mogamulizumab before or during radiotherapy at three institutions between 2012 and 2017. Results: During 43 of the 46 radiotherapy courses, patients developed Grade ≤1 radiation-induced dermatitis. No patient developed Grade ≥3 radiation-induced dermatitis. No patient was prescribed ointments as prophylactic treatment for radiation-induced dermatitis. Development of radiationinduced dermatitis was not significantly associated with the number of days since the administration of mogamulizumab prior to radiotherapy (P = 0.85), frequency of administration of mogamulizumab before/during radiotherapy (P = 0.33), administration of mogamulizumab during radiotherapy (P = 0.41) or types of lesions in adult T-cell leukaemia/lymphoma cases (cutaneous vs. noncutaneous, P = 0.74). Development of radiation-induced dermatitis was significantly related to the total cutaneous dose (mean, 31.9 Gy [95% confidence interval: 26.6-37. 
Introduction
Adult T-cell leukaemia/lymphoma (ATL) is a peripheral T-cell neoplasm with a poor prognosis caused by human T-cell leukaemia virus type 1 (1) (2) (3) (4) . ATL is classified into the following four clinical subtypes: acute, lymphoma, chronic and smouldering (1) . Acute, lymphoma and chronic subtypes are considered aggressive with short median survivals. In contrast, the more favourable chronic and smouldering subtypes have relatively long median survivals and are considered indolent ATL (5) .
Currently, a regimen of VCAP-AMP-VECP (vincristine, cyclophosphamide, doxorubicin, prednisolone; doxorubicin, ranimustine, prednisolone; vindesine, etoposide, carboplatin, prednisolone) is considered as the standard treatment for aggressive ATL (6); however, the outcome is unsatisfactory.
CC chemokine receptor 4 (CCR4) is expressed on tumour cells derived from most patients with ATL (7, 8) . Mogamulizumab is a defucosylated humanised monoclonal antibody targeting CCR4 (9) . A higher percentage of complete remission (CR) was achieved with the regimen of mogamulizumab plus VCAP-AMP-VECP than VCAP-AMP-VECP alone in a randomised Phase II study (10) . Although increased toxicity resulting from the combination therapy has been reported, it may become the standard treatment for ATL in the future.
Cutaneous adverse reactions (CAR) are frequently induced by mogamulizumab (11) . Although the development of CAR as a result of treatment with mogamulizumab has been reported as a favourable indication of efficacy in patients with refractory or relapsed ATL (12) , a few patients experienced severe cutaneous events. Stevens-Johnson syndrome occurred in 1.3% of patients treated with mogamulizumab (11, (13) (14) (15) . In addition, toxic epidermal necrolysis (16, 17) and severe photosensitivity (18) related to mogamulizumab have been reported, although the frequency of their occurrence is unknown.
Dermatitis is common in patients undergoing radiotherapy (RT) as well. RT is effective for symptomatic relief in patients with ATL (19) (20) (21) , although it is rarely used as treatment for ATL (4) .
Mogamulizumab has also exhibited its clinical efficacy in patients with other CCR4-positive relapsed peripheral T-cell lymphomas and cutaneous T-cell lymphomas (14) . RT is a treatment option for these diseases and is primarily administered as adjuvant, salvage or palliative therapy (22) (23) (24) (25) .
Considering mogamulizumab and RT are used for treating ATL, they can potentially be administered to the same patient. However, to our knowledge, no study has reported the combined use of mogamulizumab and RT for treating ATL. Furthermore, whether severe radiation-induced dermatitis (RID) would develop in patients receiving RT after mogamulizumab remains unclear.
In this retrospective study, we reviewed patients who underwent RT after receiving mogamulizumab for the treatment of ATL at three institutions. The aim of this study was to examine whether severe acute RID occurred during RT performed after the administration of mogamulizumab.
Patients and methods

Patients
We reviewed a total of 46 sites in 15 consecutive patients with ATL who underwent RT after receiving mogamulizumab at three hospitals: University of the Ryukyus Hospital (URH) (nine sites in seven patients), Okinawa Prefectural Nanbu Medical Center & Children's Medical Center (NMC) (five sites in four patients) and Nanbu Tokushukai Hospital (NTH) (32 sites in four patients), between 2012 and 2017. One case of whole cutaneous irradiation was defined as irradiation to one site. Total body irradiation as a pretreatment for hematopoietic stem cell transplantation was excluded from this study because whole cutaneous was not usually fully assessed in these cases.
When a patient received more than one course of RT, the patient's age and performance status (PS) were determined at the start of the first course.
ATL was diagnosed based on clinical manifestation, evidence of antibodies to human T-cell leukaemia virus type 1 in the serum and pathological confirmation of T-cell leukaemia/lymphoma. Patients were classified as having acute, lymphoma, chronic or smouldering subtypes in accordance with the Shimoyama Classification (1).
All patients were evaluated weekly by a radiation oncologist during RT. Before and after RT, all patients were treated and assessed by a haematological oncologist. Physical examinations, blood tests, computed tomography, magnetic resonance imaging and positron emission tomography with 2-deoxy-2-fluoro-D-glucose integrated with computed tomography were used for patient assessment. The timing and the method of assessment were at the discretion of the radiation or haematological oncologist. Patients were referred to a dermatologist when deemed necessary by the radiation or haematological oncologist.
Both CAR to mogamulizumab and RID were evaluated according to the Common Terminology Criteria for Adverse Events Version 4.0 (26) . Moreover, we examined whether RID was treated with ointments or painkillers. Where no description of cutaneous symptoms or prescriptions existed in the medical records, we assumed that the patient had no adverse cutaneous events.
Treatment response to RT was assessed using the Japan Clinical Oncology Group criteria for ATL modified according to the International Consensus Meeting recommendations (2) . Unconfirmed complete remission (uCR) was also defined as partial remission (PR) in this study, because distinguishing exactly between uCR and PR was difficult.
Follow-up was from the date of first RT to patient death or the last hospital visit. Late adverse events of radiation were scored according to the toxicity criteria of the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer (27) .
This retrospective study was approved by the Institutional Review Boards of all participating institutions (No.1235 at URH, No. 46 at NMC and No. 2017002 at NTH), and the requirement for written informed consent was waived.
Radiotherapy
Photon RT was planned using Eclipse version 11.0 (Varian Medical Systems) with anisotropic analytical algorithm (calculation grid, 2 mm) at URH, Monaco version 5.11 (Elekta AB) with Monte Carlo algorithm (grid spacing, 3 mm; statistical uncertainty, 1%) or Eclipse version 7.3.10 with anisotropic analytical algorithm (calculation grid, 2.5 mm) at NMC and TomoTherapy treatment planning system Hi-Art version 5.1 (Accuray) with superposition algorithm (calculation grid, 2 mm) at NTH. Electron RT was planned on the basis of actual measured doses at URH. Electron RT was not performed at NMC and NTH in this study.
RT was delivered with Clinac iX (Varian Medical Systems) at URH, Versa HD (Elekta AB) or Clinac 21EX (Varian Medical Systems) at NMC and the TomoTherapy Hi-Art system 5.1 at NTH.
RT was administered once daily for 5 days/week at all institutions. RT source, energy, total and fractionated radiation doses and other techniques were at the discretion of the treating radiation oncologists.
Measurement of the cutaneous dose
In photon RT courses conducted at URH and NMC, a cutaneous dose was described as the maximum dose observed in a cylindershaped area, which was measured from the skin surface to 5 mm below the skin surface (Fig. 1) . The cylinder-shaped area was created on Eclipse version 11.0 at URH and on MIM Maestro version 6.7 (MIM software) at NMC. At NTH, where a new structure creation is not allowed after plan approval due to limitations of the planning system, a cutaneous dose was measured at a point within 5 mm from the skin surface where the radiation dose appeared to be highest in the distribution map of radiation dose. In electron RT course, a cutaneous dose was regarded as equal to the prescription dose.
Statistical analyses
The Student's t-test was used for analysis of continuous variables. Fisher's exact test for discrete variables was used to compare proportions. P-values <0.05 were considered statistically significant. All statistical analyses were performed with the JMP software version 12.0.1 (SAS Institute).
Results
Patients
Patient characteristics are shown in Table 1 . The median age was 69 years (range, 38-83 years). Most patients showed a relatively good PS; using the Eastern Cooperative Oncology Group (ECOG) PS scale (28) , nine patients were classified with a PS score of 0-1 and 5 with a score of 2. Fourteen of 15 patients had aggressive ATL (acute, n = 7; lymphoma, n = 7), while one patient had indolent ATL (smouldering). No patient had chronic-type ATL.
In this study, 16 courses of RT targeted cutaneous lesions, while 30 courses targeted non-cutaneous lesions, including bones, lymph nodes and the central nervous system (Table 2 ). Patients received a median of 10 cycles (range, 1-15) of mogamulizumab usually at a dose of 1.0 mg/kg before or during RT. Mogamulizumab dose was reduced to 40 and 50% in two patients each only once due to myelosuppression. Four patients received mogamulizumab alone, while 11 received combined chemotherapy (CHOP [cyclophosphamide, doxorubicin, vincristine and prednisolone], n = 4; VCAP-AMP-VECP, n = 2; VCAP, n = 1; EPOCH [etoposide, prednisolone, vincristine, cyclophosphamide and doxorubicin], n = 1; THP-COP [pirarubicin, cyclophosphamide, vincristine and prednisolone], n = 1; etoposide, n = 1; irinotecan, n = 1) with mogamulizumab.
Ten of all 15 patients experienced skin rashes before RT, whereas three patients did not; information on skin rashes before RT was insufficient for two patients. Eight of the 10 patients had undergone assessment by a dermatologist, including skin biopsies. Five of the eight patients were diagnosed with ATL eruption, one patient with CAR to mogamulizumab (Grade 3) and two patients were not diagnosed with either condition (both had skin rashes equivalent to Grade 2). The cause of skin rashes was unknown for two patients who had not been assessed by a dermatologist; the rashes were equivalent to Grade 1 and Grade 2 in one patient each.
At the start of RT, the skin within the RT fields was not intact in 20 of the 46 (43%) RT courses. Sixteen of those 20 RT courses targeted cutaneous ATL lesions; the remaining four RT courses targeted non-cutaneous lesions that had ATL eruption (n = 1) or cutaneous invasion (n = 3) within RT fields. The use of ointments for lesions within RT fields before the start of RT was confirmed in 11 of the 46 (24%) courses (steroid, n = 2; non-steroid, n = 9). No patient was prescribed ointments as prophylactic treatment for RID.
The median number of days from the last administration of mogamulizumab to RT was 32 days (range, 0-892 days). When mogamulizumab was administered during RT (n = 7), the number of days was defined as 0.
Radiotherapy
RT was aimed at symptomatic relief or local control of lesions refractory to systemic therapy. Diverse patient characteristics necessitated the use of various dose-fractionated regimens in this cohort ( Table 2 ). The median total dose prescribed was 21 Gy (range, 3-50 Gy), and the median single fraction dose was 2.0 Gy (range, 1-4 Gy). The median total cutaneous dose was 22.4 Gy (range, 3.2-43.2 Gy). The mean difference per patient between the total prescribed dose and cutaneous dose was 6.5% (range, −20 to 35%; 95% confidence interval [CI], 3.6-9.3%). Figure 1 . Cylinder-shaped area for measuring the cutaneous dose. A cutaneous dose was described as the maximum dose observed in a cylindershaped area (in yellow), which was measured from the skin surface to 5 mm below the skin surface in photon RT plans at the University of the Ryukyus Hospital and Okinawa Prefectural Nanbu Medical Center and Children's Medical Center.
Electrons were used in only one course of RT for whole cutaneous irradiation at 4 MeV; photons were used in the remaining 45 courses at 4-10 MV (6 MV, n = 36; 10 MV, n = 7; 4 and 10 MV, n = 2). Two sites were irradiated with one radiation field; one course of whole cutaneous irradiation with eight fields was included here because whole cutaneous irradiation involved eight parts, each irradiated with one field. Eight sites were irradiated with two radiation fields, four sites were irradiated with three radiation fields, 23 sites were irradiated with four radiation fields and the remaining nine sites were treated with arc therapy.
A radiation dose was described as the mean dose of the planning target volume (PTV Dmean) in two courses of RT using intensitymodulated RT technique at NMC and as the median dose of the planning target volume (PTV D50) in all 32 courses planned at NTH. In one course of electron RT, which was performed at URH, a radiation dose was delivered to the skin surface. In all other 11 courses, a radiation dose was delivered to the International Commission on Radiation Units and Measurements (ICRU) 50/62 reference point.
One patient was in a prone position during one course of RT for a lesion located on the dorsal side. Another patient received whole cutaneous irradiation in the standing position. During the remaining 44 courses, patients were treated in a supine position. All sites were irradiated without bolus.
Radiation-induced dermatitis
Patients developed Grade ≤1 RID during 43 of the 46 RT courses ( Table 3) . No patient developed Grade ≥3 RID during the total 46 courses. No patient was newly referred to a dermatologist for the treatment of RID, although eight patients had been assessed and treated by a dermatologist for cutaneous ATL lesions or CAR to mogamulizumab prior to RT. Ointments were newly prescribed for RID in five of the 46 RT courses (steroid, n = 3; non-steroid, n = 2). No patient required painkillers for RID.
Development of RID was not significantly associated with the type of lesion (cutaneous vs. non-cutaneous, P = 0.74), the number of days from the last administration of mogamulizumab to RT (P = 0.85), the frequency of administration of mogamulizumab before and during RT (P = 0.33) or the presence or absence of mogamulizumab administration during RT (P = 0.41). Development of RID was significantly related to the total prescribed dose (mean, 31. Development of RID was not significantly different between the groups that used ointment and those that did not use ointment at the beginning of RT (P = 0.074), although development of RID was observed in one of 11 RT courses, in which ointment was used before RT.
Response to radiotherapy, survivals and late adverse events RT could achieve CR, PR, stable disease (SD) or progressive disease (PD) in 10.0% (n = 4), 47.5% (n = 19), 40% (n = 16) and 2.5% (n = 1) of all 40 evaluable sites, respectively. Six sites were not assessable for treatment response to RT because the general condition rapidly worsened during RT in some patients, and assessment of local lesions was insufficient in such cases. The mean total radiation dose for the CR/PR group was 27.4 Gy (95% CI: 22.8-31.9 Gy), which was significantly higher than that for the SD/PD group at 17.6 Gy (95% CI: 12.3-23.0 Gy) (P = 0.0077).
In addition, treatment response to first course of RT per patient was examined to reduce the influence of bias. CR was achieved in one patient, PR was achieved in eight patients and SD was achieved in five patients in their first course of RT. Treatment response to first course of RT was unknown in one patient because the assessment of the local lesion was insufficient.
Nine of the 15 patients received additional systemic therapy after RT. Two patients received mogamulizumab alone, five patients received chemotherapy alone (DHAP [dexamethasone, high-dose cytarabine, cisplatin], n = 1; CHASE [cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide], n = 1; CHOP, n = 1; lenalidomide, n = 1; etoposide, n = 1) and two patients received combined mogamulizumab and chemotherapy (mogamulizumab + VCAP, n = 2). Two patients also received hematopoietic stem cell transplantation after RT. At the time of the last follow-up, four patients were alive, while 11 patients had died. The median follow-up was 84 days (range, 18-301 days). No patient exhibited late adverse events related to RT.
Discussion
This study investigated RID during RT after the administration of mogamulizumab. As mogamulizumab is a new therapeutic agent for ATL, in the future, more patients may undergo RT after receiving mogamulizumab.
Grade 0-1 RID developed in 43 of the 46 courses of RT. Possible reasons that RID was mild in most cases included (i) total cutaneous doses were <40 Gy in most (41/46) RT courses and (ii) photons, instead of electrons, were used in most cases (45/46 sites).
Development of RID was observed in one of the 11 RT courses where ointment was used before RT, although no significant association was observed perhaps due to the small number of patients in this study. However, the effectiveness of ointment as prophylactic treatment for RID in patients who underwent RT after receiving mogamulizumab remains unclear as none of the patients in this study were prescribed ointment for that purpose.
Here, RID appeared to be less severe than in another study that investigated RT in patients with ATL who did not receive mogamulizumab (19) . Moreover, in our study, the development of RID was not significantly associated with the number of days from the last administration of mogamulizumab to RT, the frequency of mogamulizumab administration before or during RT or the presence or absence of mogamulizumab administration during RT. Therefore, mogamulizumab did not appear to worsen RID during subsequent RT.
Treatment response to RT was worse than that reported by Simone et al. (19) . In their study, CR or PR was achieved in all cases. This difference in local response rates may be due to the inclusion of many sites treated with very low total radiation doses in the current study; in their study, a median total dose of 30 Gy (range, 12-60 Gy) was administered, whereas in the current study, a median total dose of 21 Gy (range, 3-50 Gy) was used.
This study had several limitations. The number of patients was small, and the study was conducted retrospectively. RT techniques or regimens of combined chemotherapy were diverse. A cutaneous dose was described as a point dose due to the limitations of the planning system at NTH; therefore, it was difficult to evaluate the dose-volume histogram. An inter-observer error probably occurred on measurement of the cutaneous dose at NTH due to the measuring technique used; however, the occurrence of an inter-observer error would be acceptable because the calculation of skin dose on the treatment planning systems may contain an error of~±25% (29) (30) (31) (32) (33) (34) (35) . Lower doses were used in most RT courses in this study than the dose of 40-60 Gy that is empirically and frequently used to treat aggressive peripheral T-cell lymphoma; therefore, it remains unclear if severe RID would occur during high-dose cutaneous irradiation. The skin condition before RT was different for each patient, and no unified policy was established regarding the use of ointment during RT. The number of RID events may have been underestimated since patients with no description of cutaneous symptoms in their medical records were regarded as having no adverse cutaneous events. ATL lesions and CAR were frequently difficult to distinguish. Treatment response to RT was influenced by Table 3 . chemotherapy or mogamulizumab. Moreover, the follow-up period was short and late adverse events remain obscure.
In conclusion, none of 15 patients developed Grade ≥3 RID during a total of 46 courses of moderate-dose RT after receiving mogamulizumab. However, the safety of RT after the administration of mogamulizumab is not fully investigated. Careful attention is required during RT after the administration of mogamulizumab.
